# Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Source: https://onco.cc/trials/nct05429632/  
OnCo record `nct05429632` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of mocravimod in acute myeloid leukaemia, run by Priothera SAS, now recruiting.

## Summary

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT is a phase 3 interventional study registered as NCT05429632 by Priothera SAS, with 366 participants planned, started 2022-06-16 and due to reach its primary completion in 2027-05. Interventions recorded: mocravimod.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05429632
- Phase: 3
- Setting: Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
- Sponsor: Priothera SAS
- Enrolled: 366

## Sources

- ClinicalTrials.gov NCT05429632: https://clinicaltrials.gov/study/NCT05429632

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)

---
JSON: https://onco.cc/api/v1/entities/nct05429632.json